Have known sensitivity to any component of bevacizumab
Have known sensitivity to any component of paclitaxel
History of known radiation sensitivity syndrome
Subject has a known sensitivity to any of the components of the investigational product AGS62P1:
Known sensitivity to any of the products or components to be administered during dosing.
Pts with known sensitivity to any immunomodulatory drugs (IMiDs)
Known sensitivity to any of the products or components to be administered during dosing.
Known sensitivity or allergy to murine products or any component of RO6870810, venetoclax, or rituximab.
Known sensitivity to immunoglobulins or any of the components to be administered during dosing.
Has had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.
Subject with known sensitivity to starch or starch-derived materials;
Known sensitivity to conductive hydrogels
Previously known hypersensitivity to any of the agents used in this study; known sensitivity to melphalan
Known sensitivity to any of the ingredients of the investigational product enfortumab vedotin (ASG-22CE)
Patient has known sensitivity to any of the products to be administered during dosing
Known contraindications to radiotherapy including but not limited to radiation sensitivity syndromes such as xeroderma pigmentosum and ataxia telangiectasia mutated
Known allergic reactions, irritations or sensitivity to the active ingredients or other components of SOR007;
Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing
Known sensitivity to any of the study medication components
Known previous history of sensitivity to talimogene laherparepvec or any of its components to be administered during dosing (e.g. sorbitol, myo-inositol)
Subject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products
Has known sensitivity to any of the ingredients of:
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Patients with a known sensitivity to any of the products to be administered during treatment
Patients with preexisting known or suspected radiation sensitivity syndromes will be excluded
Known sensitivity to kanamycin and other aminoglycosides; patients with known hypersensitivity to kanamycin or any other aminoglycoside antibiotic will be excluded
Known sensitivity to any of the products to be administered during dosing
Patients with a known history of a severe allergy or sensitivity to wheat gluten
Known or suspected drug sensitivity to cytarabine or the investigational agent ficlatuzumab
Patients with known sensitivity to any immunomodulatory drugs (IMiDs)
History of sensitivity to, or history of conditions that are known to cause sensitivity to, radiation therapy
Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products
Known sensitivity to any study medication
Known sensitivity to E. coli derived products.
Have a known sensitivity to any of the components of Andes-1537
Patients with known sensitivity to alcohol.
217 Subject has known sensitivity to immunoglobulins or any of the products or components to be administered during dosing.
Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.
Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
Known sensitivity to any of the products to be administered during the study (e.g., calcium, or vitamin D)
Has known sensitivity to retinoic acid derivatives
Subject has known sensitivity to any of the components of the investigational product AGS67E:
Sensitivity score =< 3
Patient must not have known sensitivity to TRC102 or any formulation excipients
Known sensitivity to any component of cisplatin, carboplatin or pemetrexed.
Known sensitivity to any of the ingredients of the investigational product AGS15E
Known sensitivity to E. coli derived products or known sensitivity to any of the products to be administered during dosing
Has known sensitivity to capecitabine or metabolites
Sensitivity to any of the study medications or any of the ingredients or excipients of these medications
Patients with a known sensitivity to any of the products to be administered during treatment and assessments.
Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials
Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
Patients with known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Patients with known sensitivity to retinoic acid derivatives
Known sensitivity to any of the components of the investigational product AGS67E:
Prior sensitivity to plerixafor
Patients have known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D)
Known sensitivity to ferumoxytol
Sensitivity to conductive hydrogels
Known sensitivity to any of the products that will be administered during the study
Patient must not have known sensitivity to terameprocol or any formulation excipients
History of sensitivity to any component of SD-101
Patients with known sensitivity or allergy to any components of AMP-224
Known sensitivity to TAS-102, CPT-11, Bevacizumab, or their components
Known sensitivity to any of the ingredients of the investigational product AGS-16C3F
Known sensitivity or contraindication to any component of study treatment
Has a known sensitivity to 5-FU
Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or IMC-18F1, or other agents that specifically target VEGF
Subject has known sensitivity or allergy to heparin
Known sensitivity to bendamustine
Known sensitivity to mannitol
Subject has known sensitivity to any of the products to be administered during dosing
Women with sensitivity to silver
Known sensitivity to omalizumab
Known sensitivity to conductive hydrogels.
Known sensitivity or allergy to fish or fish oil
Patients with known sensitivity or allergy to porcine materials
Sensitivity to silver
Sensitivity to amide-type local anesthetics
Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
Subjects with a known sensitivity to any of the Investigational Product components
Have sensitivity or allergy to fish and/or shellfish
Have sensitivity or allergy to soy and/or soybeans
Known sensitivity to any of the components of the Levulan Kerastick for topical solution
Known sensitivity or allergy to fish
Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D)
Known sensitivity or allergy to turmeric spices or curry
Subjects with known sensitivity to any device or products required for the RALP surgery; and
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products
Demonstrate hyperinsulinemia with a quantitative insulin sensitivity check index (QUICK I) value =< 0.357
Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).
Known sensitivity to fluorescent light
Known sensitivity to 18F FSPG or components of the preparation
Known sensitivity to fluorescent light
Known sensitivity to any of the study medication components or the chemotherapy regimen
A known history of contrast sensitivity
Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
Known Stage IV ovarian cancer with brain metastases 14. Received an investigational agent in another clinical trial within 30 days prior to surgery 15. Known sensitivity to fluorescent light
Known or suspected sensitivity to diagnostic imaging contrast agents.
Known or suspected sensitivity to indocyanine green (ICG).
Known sensitivity to fluorescent light
Subject has known sensitivity to any of the products or components to be administered during dosing.
